<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01339377</url>
  </required_header>
  <id_info>
    <org_study_id>CT2-IPP-001-AO</org_study_id>
    <nct_id>NCT01339377</nct_id>
  </id_info>
  <brief_title>Safety and Effectiveness Study of the AO-1000 Device to Treat Contained Herniated Discs</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety and Effectiveness of Ozone Generated and Injected by the AO-1000 Device in the Treatment of Contained Herniated Discs</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ActiveO Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ActiveO Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety and effectiveness of the AO-1000 device to treat and relieve the pain&#xD;
      of symptomatic subjects with contained herniated discs. This single-arm pilot study will be&#xD;
      used as a go vs. no-go decision on performing a randomized-controlled trial.&#xD;
&#xD;
      The study's primary effectiveness objective is to demonstrate that the patient's&#xD;
      functionality (based on Oswestry Disability Index scores) has improved from baseline at one&#xD;
      month. The study's primary safety objective is to demonstrate that serious device/procedure&#xD;
      related adverse events and subsequent surgical interventions are no greater than those in a&#xD;
      literature control of other percutaneous disc decompression procedures at discharge, 1 month,&#xD;
      6 months, and 12 months post-treatment.&#xD;
&#xD;
      Secondary objectives are to demonstrate procedural success and improvement in the pain and&#xD;
      function of the subjects at 1, 6, and 12 months using the VAS and ODI scales as well as&#xD;
      tracking analgesic medication use. Pain and function scores for each follow-up time will be&#xD;
      compared to the baseline scores.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The AO-1000 device provides an oxygen-ozone treatment for contained herniated discs. An&#xD;
      oxygen-ozone treatment is a minimally invasive injection for treating disc herniations that&#xD;
      is widely practiced in Europe and Asia. This treatment involves the injection of an&#xD;
      oxygen-ozone mixture into the herniated disc and/or the paravertebral muscle surrounding the&#xD;
      disc. However, there are no medical ozone generators for this procedure that are currently&#xD;
      cleared by the FDA for use in the US. Many studies using a wide range of inclusion/exclusion&#xD;
      criteria, ozone concentrations, and procedures have been performed to determine the&#xD;
      effectiveness of oxygen-ozone treatment.&#xD;
&#xD;
      A meta-analysis of nearly 8,000 patients from published studies shows a mean improvement of&#xD;
      39 mm for VAS and 25.7 for ODI. The likelihood of complications was 0.064%. Furthermore, no&#xD;
      cases of discitis were reported after oxygen-ozone therapy, which is unlike all the other&#xD;
      methods of disc volume reduction. This is most likely due to the fact that ozone is a strong&#xD;
      oxidizer and an excellent disinfecting agent. The complications shown in the meta-analysis&#xD;
      were minor and transient, and easily avoidable by utilizing a device such as the AO-1000 that&#xD;
      is designed to eliminate these types of complications (ozone leakage into the treatment room&#xD;
      and high ozone concentrations) during this procedure. The estimated complication rate from&#xD;
      the meta-analysis is consistent with the Italian Oxygen-Ozone Therapy Federation (FIO)&#xD;
      results (no procedure-related adverse events in treatments on 15,000 patients).&#xD;
&#xD;
      The safety of the direct injection of oxygen-ozone gas mixture into the nucleus pulposus was&#xD;
      well established in these studies. Therefore, the intent of this study is to obtain data to&#xD;
      confirm that a 2 weight percent (wt%) oxygen-ozone mixture delivered from the AO-1000 device&#xD;
      is safe and effective for the intended use. This clinical study is designed to bridge the&#xD;
      AO-1000 to the extensive prior oxygen-ozone treatment safety and effectiveness data between&#xD;
      studies such as those found in the Meta-analysis that did not use the AO-1000 as the delivery&#xD;
      system.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Primary Effectiveness Endpoint: Change from Baseline ODI Score at 1 Month</measure>
    <time_frame>1 month post-treatment</time_frame>
    <description>Mean change from baseline ODI score, analyzed at 1 month. The endpoint will be deemed successful if the mean improvement is statistically shown (p&lt;0.05) to be at least 15 points (the minimum detectable change of the ODI).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Primary Safety Endpoint: Frequency of Serious Adverse Events Compared to Literature Control</measure>
    <time_frame>12 months post-treatment</time_frame>
    <description>The endpoint will be deemed successful if the number of serious device/procedure related adverse events are statistically shown (p&lt;0.05) to be no greater than those in a literature control of other percutaneous disc decompression procedures.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Functional improvement</measure>
    <time_frame>6 and 12 months post-treatment</time_frame>
    <description>Mean change from baseline ODI score, analyzed at 6 and 12 months. Each endpoint will be deemed successful if the mean improvement is statistically shown (p&lt;0.05) to be at least 15 points (the minimum detectable change of the ODI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Leg and Back Pain Improvement</measure>
    <time_frame>1, 6, and 12 months post-treatment</time_frame>
    <description>Mean change from separate leg and back pain baseline Visual Analog Scale (VAS) scores, analyzed at 1, 6, and 12 months. Each endpoint (leg VAS and back VAS at each follow-up time) will be deemed successful if the mean improvement is statistically shown (p&lt;0.05) to be at least 20 mm (the minimum clinically important difference of the VAS).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural Success</measure>
    <time_frame>Time of Treatment</time_frame>
    <description>Technical success, as assessed by successful injection of oxygen-ozone mixture confirmed via CT scan performed immediately following the treatment. A treatment will be considered a success if the CT scan shows gas within the target disc.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analgesic Medication Use</measure>
    <time_frame>1, 6, and 12 months post-treatment</time_frame>
    <description>Change in prescription and over-the-counter (OTC) analgesic medication use, including non-steroidal anti-inflammatory drugs (NSAIDs) from baseline, analyzed at 1, 6, and 12 months. Endpoint will be deemed successful if the number of patients using analgesic medication decreases from baseline.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>Disk, Herniated</condition>
  <arm_group>
    <arm_group_label>AO-1000 Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oxygen-ozone treatment with the AO-1000 device</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>AO-1000</intervention_name>
    <description>Mixture of 2 weight% ozone in 98 weight% oxygen injected into the nucleus pulposus of a contained herniated disc.</description>
    <arm_group_label>AO-1000 Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 to 70 years of age&#xD;
&#xD;
          -  Herniated disc between L1 and S1 evident on diagnostic imaging&#xD;
&#xD;
          -  Sciatica with or without lower back pain for &gt; 3 months&#xD;
&#xD;
          -  Failure to improve with non-operative care (Conservative treatment failure)&#xD;
&#xD;
          -  Sciatica with or without lower back pain exacerbated by sitting and/or standing with&#xD;
             recumbent relief&#xD;
&#xD;
          -  A preoperative leg or back VAS (pain) score between 40 and 90 mm on a 100 mm scale.&#xD;
             (moderate to severe pain)&#xD;
&#xD;
          -  A preoperative ODI (function) score between 40 and 90 (moderate to severe functional&#xD;
             disability)&#xD;
&#xD;
          -  Able and willing to return for the follow-up evaluations&#xD;
&#xD;
          -  The pain must be consistent with the dermatome pattern and must be clearly&#xD;
             identifiable to the herniated disc.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Functional neurological deficit evident during neurological exam&#xD;
&#xD;
          -  Previous spine surgery in the lumbar region or adjacent to the disc of interest&#xD;
&#xD;
          -  Cord compression or cauda equine syndrome&#xD;
&#xD;
          -  Structural deformities (e.g. spondylolisthesis, greater than a mild degree of&#xD;
             non-discogenic vertebral canal stenosis, greater than a mild degree of scoliosis,&#xD;
             spinal fracture, disc herniations &gt; 4 mm, sequestered herniation)&#xD;
&#xD;
          -  Extruded/free disc fragment&#xD;
&#xD;
          -  Calcified disc fragment&#xD;
&#xD;
          -  Disc height loss &gt; 75%&#xD;
&#xD;
          -  Inaccessible disc due to, for example, overlap of the iliac wings, and/or steep&#xD;
             angulation of the L5/S1 disc space&#xD;
&#xD;
          -  Coagulopathy evident on blood sample testing&#xD;
&#xD;
          -  Platelet count &lt; 50,000&#xD;
&#xD;
          -  International Normalized Ratio (INR) &gt; 1.4&#xD;
&#xD;
          -  Partial Thromboplastin Time (PTT) &gt; 1.3&#xD;
&#xD;
          -  White blood cell count (WBCC) &gt; 12,000&#xD;
&#xD;
          -  Infection as evidenced by subject clinical evaluation, history, and blood test&#xD;
&#xD;
          -  Any evidence of osteomyelitis/discitis at any level&#xD;
&#xD;
          -  Uncontrolled/acute illness&#xD;
&#xD;
          -  Women who are pregnant&#xD;
&#xD;
          -  Worker's compensation, injury litigation, disability remuneration&#xD;
&#xD;
          -  Participation in another clinical investigation or course of care that may confound&#xD;
             the outcome of this study&#xD;
&#xD;
          -  Smoker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V5Z 1M9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Western Ontario - London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6H 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Steppan J, Meaders T, Muto M, Murphy KJ. A metaanalysis of the effectiveness and safety of ozone treatments for herniated lumbar discs. J Vasc Interv Radiol. 2010 Apr;21(4):534-48. doi: 10.1016/j.jvir.2009.12.393. Epub 2010 Feb 25. Review.</citation>
    <PMID>20188591</PMID>
  </reference>
  <reference>
    <citation>Pellican√≤ G, Martinelli F, Tavanti V, et al. The Italian Oxygen-Ozone Therapy Federation (FIO) Study on Oxygen-Ozone Treatment of Herniated Disc. Int J Ozone Ther 6:7-15, 2007.</citation>
  </reference>
  <reference>
    <citation>Oder B, Loewe M, Reisegger M, Lang W, Ilias W, Thurnher SA. CT-guided ozone/steroid therapy for the treatment of degenerative spinal disease--effect of age, gender, disc pathology and multi-segmental changes. Neuroradiology. 2008 Sep;50(9):777-85. doi: 10.1007/s00234-008-0398-2. Epub 2008 May 16.</citation>
    <PMID>18483728</PMID>
  </reference>
  <reference>
    <citation>Mixter WJ, Barr JS. Rupture of the intervertebral disc with involvement of the spinal canal. N Engl J Med 211:210-215, 1934.</citation>
  </reference>
  <reference>
    <citation>Andreula CF, Simonetti L, De Santis F, Agati R, Ricci R, Leonardi M. Minimally invasive oxygen-ozone therapy for lumbar disk herniation. AJNR Am J Neuroradiol. 2003 May;24(5):996-1000.</citation>
    <PMID>12748111</PMID>
  </reference>
  <reference>
    <citation>Andreula C, Muto M, Leonardi M. Interventional spinal procedures. Eur J Radiol. 2004 May;50(2):112-9. Review.</citation>
    <PMID>15081127</PMID>
  </reference>
  <reference>
    <citation>Bonetti M, Fontana A, Cotticelli B, Volta GD, Guindani M, Leonardi M. Intraforaminal O(2)-O(3) versus periradicular steroidal infiltrations in lower back pain: randomized controlled study. AJNR Am J Neuroradiol. 2005 May;26(5):996-1000.</citation>
    <PMID>15891150</PMID>
  </reference>
  <reference>
    <citation>Gallucci M, Limbucci N, Zugaro L, Barile A, Stavroulis E, Ricci A, Galzio R, Masciocchi C. Sciatica: treatment with intradiscal and intraforaminal injections of steroid and oxygen-ozone versus steroid only. Radiology. 2007 Mar;242(3):907-13. Epub 2007 Jan 5.</citation>
    <PMID>17209164</PMID>
  </reference>
  <verification_date>July 2016</verification_date>
  <study_first_submitted>April 19, 2011</study_first_submitted>
  <study_first_submitted_qc>April 19, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 20, 2011</study_first_posted>
  <last_update_submitted>July 13, 2016</last_update_submitted>
  <last_update_submitted_qc>July 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 15, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Ozone</keyword>
  <keyword>Oxygen</keyword>
  <keyword>Oxygen-Ozone</keyword>
  <keyword>AO-1000</keyword>
  <keyword>ActiveO</keyword>
  <keyword>Herniated Disc</keyword>
  <keyword>Disc</keyword>
  <keyword>Lumbar</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Intervertebral Disc Displacement</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

